Pancrelipase Delayed Release

DRUG3 trials

Sponsors

Solvay Pharmaceuticals

Conditions

Cystic FibrosisPancreatic Exocrine Insufficiency

Phase 3

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

CompletedNCT00510484

Solvay PharmaceuticalsCystic Fibrosis

Start: 2007-11-30End: 2008-03-31Updated: 2010-06-03

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

CompletedNCT00690820

Solvay PharmaceuticalsCystic Fibrosis, Pancreatic Exocrine Insufficiency

Start: 2008-06-30End: 2008-12-31Updated: 2010-06-02

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

CompletedNCT00775528

Solvay PharmaceuticalsCystic Fibrosis, Pancreatic Exocrine Insufficiency

Start: 2009-04-30End: 2009-06-30Updated: 2010-11-08

Related Papers

Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.

2010-01-0144 citations